Mylan N.V. (NASDAQ:MYL) has today made an announcement which is most probably great news for all those patients that have been struggling with HIV/AIDS. HIV/AIDS has claimed the lives of quite a large number of people around the world and from the word and it continues every day.
The worst bit about this complication lies in the idea that it has been presumed to have no cure. However, truth be told, much has been going on in the research arena with medical schools and top companies directing much towards establishing the cures for HIV/AIDS. Mylan happens to be one of the most renowned as well as trusted global pharmaceutical companies and has been doing pretty well in the world markets in terms of business success.
The announcement today is a positive step for the company but as pointed out earlier, the suffering patients are the happiest after receiving the news that the company had announced receipt of approval from the U.S. Food and Drug Administration under the U.S. President’s Emergency Plan for AIDS Relief for the New Drug Application for Lamivudine, Efavirenz and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg (“TLE400”). TLE400.
This is an antiretroviral fixed-does combination which according to inside sources will be made readily available in most of the developing countries serving as a first-line regimen for persons under HIV/AIDS medication.
Mylan in the recent past has been laying down strategies and plans that would help it showcase its dedication to increasing access of HIV/AIDS treatments to patients in most of the developing countries.
In a bid to maintain constant supply, the company has set up some nine independent sites all of them engaged in the production as well as the supply of the ARV products.
As a giant global pharmaceutical company, Mylan is showing great commitment in the setting up of the newest standards in healthcare. It is a great move that it has at the moment succeeded in providing about 7 billion people with quick access to high quality medicine. Its innovative edge targets the unmet needs, something that some of its competitors fail at miserably.
